AD causes dry, itchy, and inflamed skin.

This study will collect information from adolescents and adults who use an approved medication called lebrikizumab. Lebrikizumab blocks a specific protein in the body that causes inflammation and itchy skin.

Researchers want to understand how lebrikizumab works for people with different health backgrounds. The study is also looking at how well lebrikizumab works when people take it for a long time.

About 400 people will participate.

Why is the study important?

Lebrikizumab has been studied in adolescents and adults with AD, but more information is needed on how it works in different people in the real world. The results from this study may help researchers and doctors find better ways to help people with AD in the future.

What will the study involve?

You will be in the study for a little over 2 years.

Part 1: Is the study right for you? (up to 3 months)

Your treating doctor or their study team will check your medical records to see if the study is right for you.

Part 2: If the study is right for you (about 2 years)

You will continue to visit your treating doctor, as scheduled, for your care.

• You will share information about you, your condition, and lebrikizumab.
• You will have 4 scheduled visits in the first year, and 2 scheduled visits in the second year.
• You will answer some questionnaires at specific visits.
• The prescription for lebrikizumab you will receive is not provided as part of the study.

Who can take part?

People who:

• are 12 years of age or older
• have a diagnosis of moderate-to-severe AD
• have been prescribed lebrikizumab but have not yet taken the first dose.

What else do I need to consider?

• You do not have to take part in the study.
• If you choose to take part, you can stop participating at any time.
• An Institutional Review Board (IRB)/Research Ethics Board (REB), which protects the rights, safety, and well-being of participants, reviewed this study.